Also published in Business Insider:
GMI Ratings Governance Issue | Northrop Grumman Corp.
x hide permanently

Celgene is Buying Cancer Drugmaker Juno Therapeutics for $9 Billion

Business Insider
  • Celgene is acquiring Juno Therapeutics, a company developing personalized cancer treatments in a deal worth $9 billion.
  • It's the second deal in 2018 for the biotech giant, which has been under pressure from investors.
  • The highly personalized treatments Juno makes, called CAR T-cell therapy, are at the beginning of what some are calling "a big new field of medicine...
Mentions: Investors CEO acquisition